BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp. > Keep your eyes on the short report

<< Previous

Bullboard Posts

Next >>

Comment by TheWeakendzon Jul 06, 2022 9:25pm

104 Views

Post# 34807101

RE:RE:Keep your eyes on the short report

frankman wrote: The shares are insignificant position is most likely already covered from the rising price which the short report is only dated up to June 30th. And the price rose after July 4th so ignore it.

You could be right, but if the short position rises dramatically, I might dump my entire position. Anything over 250k would make me wonder????? A cure for anything is no game, but the stock market, well, it is what it is. Jmo. Glta

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023